PH24716A - Stabilized human tissue plasminogen activator compositions - Google Patents

Stabilized human tissue plasminogen activator compositions

Info

Publication number
PH24716A
PH24716A PH34602A PH34602A PH24716A PH 24716 A PH24716 A PH 24716A PH 34602 A PH34602 A PH 34602A PH 34602 A PH34602 A PH 34602A PH 24716 A PH24716 A PH 24716A
Authority
PH
Philippines
Prior art keywords
plasminogen activator
human tissue
tissue plasminogen
activator compositions
stabilized human
Prior art date
Application number
PH34602A
Other languages
English (en)
Inventor
William F Bennett
Stuart E Builder
Larry A Gatlin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25205495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH24716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PH24716A publication Critical patent/PH24716A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH34602A 1985-12-17 1986-12-16 Stabilized human tissue plasminogen activator compositions PH24716A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/811,081 US4777043A (en) 1985-12-17 1985-12-17 Stabilized human tissue plasminogen activator compositions

Publications (1)

Publication Number Publication Date
PH24716A true PH24716A (en) 1990-10-01

Family

ID=25205495

Family Applications (1)

Application Number Title Priority Date Filing Date
PH34602A PH24716A (en) 1985-12-17 1986-12-16 Stabilized human tissue plasminogen activator compositions

Country Status (23)

Country Link
US (2) US4777043A (pt)
EP (1) EP0228862B1 (pt)
JP (2) JPH0714886B2 (pt)
KR (1) KR950010322B1 (pt)
AT (1) ATE79273T1 (pt)
AU (1) AU600246B2 (pt)
DD (1) DD255477A5 (pt)
DE (2) DE3642960A1 (pt)
DK (1) DK174203B1 (pt)
ES (1) ES2044840T3 (pt)
FI (1) FI88873C (pt)
FR (1) FR2591485B1 (pt)
GB (1) GB2184354B (pt)
GR (1) GR3006078T3 (pt)
HU (1) HU200101B (pt)
IE (1) IE59060B1 (pt)
IL (1) IL80904A (pt)
MY (1) MY102185A (pt)
NO (1) NO168988C (pt)
NZ (1) NZ218612A (pt)
PH (1) PH24716A (pt)
PT (1) PT83933B (pt)
ZA (1) ZA869457B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687255T2 (de) * 1985-09-10 1993-05-06 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
JP2708749B2 (ja) 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
DE19606551C2 (de) * 1996-02-22 2000-06-08 Basotherm Gmbh rt-PA zur Prävention des Nachstars nach Kataraktoperation
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
AU6558400A (en) * 1999-08-17 2001-03-13 Novo Nordisk A/S Stabilisation of freeze-dried cake
AU781023B2 (en) 1999-11-04 2005-04-28 Genentech Inc. Reversed-phase HPLC assay for plasminogen activators
CA2403962C (en) 2000-03-31 2009-12-15 Kirin Beer Kabushiki Kaisha Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20110179558A1 (en) * 2009-07-29 2011-07-28 International Enviroguard Systems, Inc. Breathable Protective Fabric and Garment
AU2014236938B2 (en) * 2013-03-14 2018-12-20 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98833C (da) * 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
DE3273732D1 (en) * 1982-12-30 1986-11-20 Kowa Co Method of producing a tissue plasminogen activator and composition comprising same
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
IL78571A (en) * 1985-04-22 1991-06-30 Genentech Inc Human tissue plasminogen activator mutants resistant to enzymatic cleavage resulting in two-chain form
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
NL8601354A (nl) * 1985-05-28 1986-12-16 Wellcome Found Nieuwe samenstelling.
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
DE3687255T2 (de) * 1985-09-10 1993-05-06 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
JPS62283932A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤

Also Published As

Publication number Publication date
JPS62164632A (ja) 1987-07-21
DE3686410D1 (de) 1992-09-17
DK174203B1 (da) 2002-09-16
DE3686410T2 (de) 1993-02-18
US4777043A (en) 1988-10-11
NO168988C (no) 1992-04-29
FI88873C (fi) 1993-07-26
FR2591485A1 (fr) 1987-06-19
GR3006078T3 (pt) 1993-06-21
FR2591485B1 (fr) 1989-07-28
NZ218612A (en) 1989-07-27
GB8629981D0 (en) 1987-01-28
ZA869457B (en) 1988-08-31
MY102185A (en) 1992-04-30
NO865079L (no) 1987-06-18
FI865159A (fi) 1987-06-18
FI88873B (fi) 1993-04-15
DD255477A5 (de) 1988-04-06
EP0228862B1 (en) 1992-08-12
HUT42955A (en) 1987-09-28
IE863279L (en) 1987-06-17
GB2184354B (en) 1990-04-11
IL80904A0 (en) 1987-03-31
DK605786A (da) 1987-06-18
AU600246B2 (en) 1990-08-09
NO168988B (no) 1992-01-20
GB2184354A (en) 1987-06-24
EP0228862A2 (en) 1987-07-15
KR870005647A (ko) 1987-07-06
JPH07173076A (ja) 1995-07-11
JPH0714886B2 (ja) 1995-02-22
DE3642960A1 (de) 1987-06-19
HU200101B (en) 1990-04-28
PT83933A (en) 1987-01-01
IL80904A (en) 1992-01-15
US4908205A (en) 1990-03-13
FI865159A0 (fi) 1986-12-17
PT83933B (pt) 1989-01-17
ATE79273T1 (de) 1992-08-15
KR950010322B1 (ko) 1995-09-14
NO865079D0 (no) 1986-12-16
IE59060B1 (en) 1993-12-15
EP0228862A3 (en) 1988-09-28
ES2044840T3 (es) 1994-01-16
DK605786D0 (da) 1986-12-16
AU6661086A (en) 1987-06-18

Similar Documents

Publication Publication Date Title
GB2184354B (en) Stabilized human tissue plasminogen activator compositions
GR3006630T3 (pt)
GR3007385T3 (pt)
IL140140A0 (en) Thyroid hormone analogues and methods for their preparation
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
HUT41002A (en) Process for preparing anticonvulsives
MY102026A (en) Antiasthmatic.
ZA891242B (en) 24r-scymnol,and preparation and use thereof
HK135494A (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
AU1235288A (en) Antidepressant compositions
GR3005231T3 (pt)
GR3003132T3 (en) Pharmaceutical compositions having healing activity
IL68195A (en) Dermatological preparations containing as active ingredients 1alpha-hydroxycholecalciferol or 1alpha,25-dihydroxy-cholecalciferol
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
AU563031C (en) Human Tissue Plasminogen Activator
AU563031B2 (en) Human tissue plasminogen activator
HU910063D0 (en) Process for the production of preparations containing synergetic combination of active agents of natural origin, usable for selective decreasing of blood lipoids